Literature DB >> 23335387

Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling.

Malin Lando1, Saskia M Wilting, Kristin Snipstad, Trevor Clancy, Mariska Bierkens, Eva-Katrine Aarnes, Marit Holden, Trond Stokke, Kolbein Sundfør, Ruth Holm, Gunnar B Kristensen, Renske D M Steenbergen, Heidi Lyng.   

Abstract

The pathogenetic role, including its target genes, of the recurrent 3p12-p14 loss in cervical cancer has remained unclear. To determine the onset of the event during carcinogenesis, we used microarray techniques and found that the loss was the most frequent 3p event, occurring in 61% of 92 invasive carcinomas, in only 2% of 43 high-grade intraepithelial lesions (CIN2/3), and in 33% of 6 CIN3 lesions adjacent to invasive carcinomas, suggesting a role in acquisition of invasiveness or early during the invasive phase. We performed an integrative DNA copy number and expression analysis of 77 invasive carcinomas, where all genes within the recurrent region were included. We selected eight genes, THOC7, PSMD6, SLC25A26, TMF1, RYBP, SHQ1, EBLN2, and GBE1, which were highly down-regulated in cases with loss, as confirmed at the protein level for RYBP and TMF1 by immunohistochemistry. The eight genes were subjected to network analysis based on the expression profiles, revealing interaction partners of proteins encoded by the genes that were coordinately regulated in tumours with loss. Several partners were shared among the eight genes, indicating crosstalk in their signalling. Gene ontology analysis showed enrichment of biological processes such as apoptosis, proliferation, and stress response in the network and suggested a relationship between down-regulation of the eight genes and activation of tumourigenic pathways. Survival analysis showed prognostic impact of the eight-gene signature that was confirmed in a validation cohort of 74 patients and was independent of clinical parameters. These results support the role of the eight candidate genes as targets of the 3p12-p14 loss in cervical cancer and suggest that the strong selection advantage of the loss during carcinogenesis might be caused by a synergetic effect of several tumourigenic processes controlled by these targets.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335387     DOI: 10.1002/path.4168

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  19 in total

1.  Inhibition of Borna disease virus replication by an endogenous bornavirus-like element in the ground squirrel genome.

Authors:  Kan Fujino; Masayuki Horie; Tomoyuki Honda; Dana K Merriman; Keizo Tomonaga
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

2.  Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.

Authors:  Malin Lando; Christina S Fjeldbo; Saskia M Wilting; Barbara C Snoek; Eva-Katrine Aarnes; Malin F Forsberg; Gunnar B Kristensen; Renske Dm Steenbergen; Heidi Lyng
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

3.  RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy.

Authors:  Sukesh Voruganti; Fangxiu Xu; Jiang-Jiang Qin; Yan Guo; Sushanta Sarkar; Ming Gao; Zhijie Zheng; Ming-Hai Wang; Jianwei Zhou; Biyun Qian; Ruiwen Zhang; Wei Wang
Journal:  Cancer Lett       Date:  2015-09-21       Impact factor: 8.679

4.  Structure and interactions of the CS domain of human H/ACA RNP assembly protein Shq1.

Authors:  Mahavir Singh; Zhonghua Wang; Duilio Cascio; Juli Feigon
Journal:  J Mol Biol       Date:  2014-12-29       Impact factor: 5.469

Review 5.  RNA-guided isomerization of uridine to pseudouridine--pseudouridylation.

Authors:  Yi-Tao Yu; U Thomas Meier
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

6.  Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome.

Authors:  Hyejin Cho; Tali Herzka; Carlos Stahlhut; Kaitlin Watrud; Brian D Robinson; Lloyd C Trotman
Journal:  Methods       Date:  2015-01-12       Impact factor: 3.608

7.  Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Authors:  Ankur Chakravarthy; Ian Reddin; Stephen Henderson; Cindy Dong; Nerissa Kirkwood; Maxmilan Jeyakumar; Daniela Rothschild Rodriguez; Natalia Gonzalez Martinez; Jacqueline McDermott; Xiaoping Su; Nagayasau Egawa; Christina S Fjeldbo; Vilde Eide Skingen; Heidi Lyng; Mari Kyllesø Halle; Camilla Krakstad; Afschin Soleiman; Susanne Sprung; Matt Lechner; Peter J I Ellis; Mark Wass; Martin Michaelis; Heidi Fiegl; Helga Salvesen; Gareth J Thomas; John Doorbar; Kerry Chester; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

8.  Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.

Authors:  Tomoya Mizuno; Takao Kamai; Hideyuki Abe; Setsu Sakamoto; Kazuhiro Kitajima; Daisaku Nishihara; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Masahiro Yashi; Yoshitatsu Fukabori; Yasushi Kaji; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2015-03-10       Impact factor: 4.430

9.  An Optimization-Driven Analysis Pipeline to Uncover Biomarkers and Signaling Paths: Cervix Cancer.

Authors:  Enery Lorenzo; Katia Camacho-Caceres; Alexander J Ropelewski; Juan Rosas; Michael Ortiz-Mojer; Lynn Perez-Marty; Juan Irizarry; Valerie Gonzalez; Jesús A Rodríguez; Mauricio Cabrera-Rios; Clara Isaza
Journal:  Microarrays (Basel)       Date:  2015-06

Review 10.  Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.

Authors:  Maria M Caffarel; Nicholas Coleman
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.